Redhill Biopharma (XTAE:RDHL) Net Interest Income : ₪-35.0 Mil (TTM As of Jun. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Redhill Biopharma Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Redhill Biopharma's net interest income for the three months ended in Jun. 2023 was ₪19.2 Mil. Its net interest income for the trailing twelve months (TTM) ended in Jun. 2023 was ₪-35.0 Mil.

Redhill Biopharma Net Interest Income Historical Data

The historical data trend for Redhill Biopharma's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Net Interest Income Chart

Redhill Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Interest Income

Get a 7-Day Free Trial

0.02

-46.74

-61.63

-156.89

-8.02

Redhill Biopharma Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Net Interest Income	Get a 7-Day Free Trial															-106.28	-26.63	78.66	19.21	-

Redhill Biopharma Net Interest Income Calculation

Net Interest Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-35.0 Mil.

Redhill Biopharma Net Interest Income Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma (XTAE:RDHL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (XTAE:RDHL) » Definitions » Net Interest Income

Comparable Companies

Traded in Other Exchanges

RDHL:USA 2RH0:Germany 2RH0:Germany

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.